Balstilimab clinical trials
Also written AGEN2034.
How each study uses balstilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the balstilimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
36 studies that test it; most in 2025 (9); 2 more planned to start later
| Year | Studies |
|---|---|
| 2017 | 2 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 7 |
| 2024 | 5 |
| 2025 | 9 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 28
Agenus Inc. (8) · City of Hope Medical Center (5) · Immune Oncology Research Institute (2) · National Cancer Institute (NCI) (2) · Memorial Sloan Kettering Cancer Center (2) · ImmunoGenesis (1) · Northwestern University (1) · University of Colorado, Denver (1)
Often tested with
Tested in the same studies.
Botensilimab (26) · Zalifrelimab (5) · Vorbipiprant (2) · TH 302 (1) · Trastuzumab deruxtecan (1) · Durvalumab (1) · Panitumumab (1) · Sotorasib (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 10
Studies that test balstilimab.
- Dec 2026Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI CancersPhase 1/2 · Rottapharm Biotech
- Jan 2027Botensilimab, Balstilimab, and SBRT in Colorectal CancerEarly Phase 1 · Massachusetts General Hospital
- Jan 2027Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal CancerPhase 1 · University of Southern California
- Apr 2027Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue SarcomasPhase 2 · University of Colorado, Denver
- May 2027Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)Phase 2 · Gruppo Oncologico del Nord-Ovest
- Jun 2027RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal CancerPhase 2 · Dana-Farber Cancer Institute
- Jun 2027FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal CancerPhase 1/2 · City of Hope Medical Center
- Sep 2027A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerPhase 2 · Agenus Inc.
- Oct 2027A Study of Evofosfamide in Combination With Zalifrelimab and BalstilimabPhase 1/2 · ImmunoGenesis
- Nov 2027FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before SurgeryPhase 2 · City of Hope Medical Center
Studies
Open first, then newest update. How each study uses balstilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 38
- RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal CancerRecruitingPhase 2Dana-Farber Cancer InstituteNCT07735624Written as Balstilimab
- Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT TrialRecruitingPhase 2National Cancer Institute (NCI)NCT07516366Written as Balstilimab
- Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3RecruitingPhase 2City of Hope Medical CenterNCT07595874Written as Balstilimab
- Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat TrialRecruitingPhase 2National Cancer Institute (NCI)NCT07551596Written as Balstilimab
- A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and ChemotherapyRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07227636Written as Balstilimab
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingPhase 2Gruppo Oncologico del Nord-OvestNCT05845450Written as Balstilimab
- The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-RadiationRecruitingPhase 2Benjamin SpielerNCT06843551Written as Balstilimab
- KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal CancerRecruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06411691Written as Balstilimab
- FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before SurgeryRecruitingPhase 2City of Hope Medical CenterNCT06780787Written as Balstilimab
- Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric AdenocarcinomasRecruitingPhase 3Centre Leon BerardNCT06346197Written as Balstilimab
- Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver MetastasisRecruitingEarly Phase 1Northwell HealthNCT07193862Written as Doxorubicin, FOLFOX, Botensilimab, Balstilimab, Bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373
- A Study of Botensilimab and Balstilimab for Rectal AdenocarcinomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06843434Written as Balstilimab
- Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)RecruitingPhase 2Immune Oncology Research InstituteNCT05891821Written as Balstilimab
- Botensilimab, Balstilimab, and SBRT in Colorectal CancerRecruitingEarly Phase 1Massachusetts General HospitalNCT07128355Written as Balstilimab
- Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal CancerRecruitingPhase 1University of Southern CaliforniaNCT06336902Written as Balstilimab
- A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerActive, not recruitingPhase 2Agenus Inc.NCT05608044Written as Balstilimab
- A Study of Evofosfamide in Combination With Zalifrelimab and BalstilimabActive, not recruitingPhase 1/2ImmunoGenesisNCT06782555Written as Balstilimab
- Combination Immunotherapy in Colorectal CancerCompletedPhase 2Weill Medical College of Cornell UniversityNCT05571293Written as Balstilimab
- Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaActive, not recruitingPhase 2Northwestern UniversityNCT05864534Written as Balstilimab
- FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal CancerActive, not recruitingPhase 1/2City of Hope Medical CenterNCT05627635Written as Balstilimab
See all 38 studies that test balstilimab →
Given beside what is tested · 13 — balstilimab is usual care or a partner of the new treatment
- BAL/BOT/agenT-797 in pMMR CRC With Liver MetastasesRecruitingPhase 2Darren Sigal, MDNCT07550088Written as Balstilimab (BAL)
- Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver MetastasesRecruitingPhase 2Weill Medical College of Cornell UniversityNCT06300463Written as Balstilimab
- A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.Not yet recruitingPhase 2Nelum CorpNCT07578337Written as Balstililmab
- rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMGRecruitingPhase 1Ann & Robert H Lurie Children's Hospital of ChicagoNCT04943848Written as Balstilimab
- Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology CombinationsRecruitingPhase 2/3The Netherlands Cancer InstituteNCT06279130Written as balstilimab
- Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic CancerRecruitingPhase 1/2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06782932Written as Balstilimab
- A Study of Botensilimab (AGEN1181) for the Treatment of Advanced MelanomaTerminatedPhase 2Agenus Inc.NCT05529316Written as Balstilimab
- A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction CancerActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06251973Written as Balstilimab
- Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerActive, not recruitingPhase 1Agenus Inc.NCT03860272Written as Balstilimab
- Study of OBT076 Associated or Not in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and NeckTerminatedPhase 1Groupe Oncologie Radiotherapie Tete et CouNCT05930951Written as Balstilimab
- Study of AGEN1571 in Participants With Advanced Solid TumorsCompletedPhase 1Agenus Inc.NCT05377528Written as Balstilimab
- Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic CancerActive, not recruitingPhase 2University of Kansas Medical CenterNCT05638698Written as Balstilimab
- A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma PatientsWithdrawnPhase 2Targovax OyNCT05561491Written as Balstilimab
Codes
What other systems call balstilimab · ClinicalTrials.gg INT001783
- MeSH (NLM) C000720935balstilimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 1Q2QT5M7EOBALSTILIMABConfirmed FDA, NLM
- NCI Thesaurus C136465BalstilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720935 | balstilimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 1Q2QT5M7EO | BALSTILIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C136465 | Balstilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.